Cheryl Cox Kinney, MD, explains when night sweats warrant further evaluation, including red flags, persistent symptoms, and potential nonmenopausal causes.
|Slideshows|October 6, 2021
September Conference Roundup for Primary Care
Author(s)Sydney Jennings
Advertisement
September was a busy month for conferences, with the 57th European Association for the Study of Diabetes (EASD) annual meeting, Infectious Disease Week (IDWeek) 2021 Annual Meeting, and the American Heart Association's (AHA) Hypertension Scientific Sessions 2021 all held virtually. In the slides below, find briefs on 9 clinical trials presented at these meetings that may impact your clinical practice.
Advertisement
Related to this article
TMS 2026: Menopause was coded in just 7.8% of midlife outpatient visits. Arina Chesnokova, MD, MPH, discusses diagnosis gaps, prescribing risks, and solutions for primary care.
Investigational CagriSema produced 23.1% to 26.7% weight loss across menopause stages at 68 weeks, with improvements in cardiometabolic risk factors.
An EHR-integrated tool matched manual CKD and cardiovascular risk assessments in 60 patients and showed promise for improving risk-based kidney care in primary care.
TMS 2026: Nearly 67% of US women receiving elinzanetant achieved at least a 50% reduction in menopausal VMS frequency by week 12 in pooled phase 3 trial data.
TMS 2026: Only 21.7% of women initiated menopause hormone therapy, with significant racial disparities and low treatment persistence, a new study finds.
TMS 2026: OB/GYN visits had nearly 4-fold higher odds of menopause coding than family medicine visits, with disparities by race and insurance, a study found.
JoAnn Pinkerton, MD, discusses new research she presented at The Menopause Society 2026 Annual Meeting on elinzanetant for menopausal vasomotor symptoms.
Advertisement
Advertisement
Trending on Patient Care Online
1
Primary Care Lens: Atrial Fibrillation From Detection to Referral in Primary Care
2
Menopause Care in Primary Care: Closing Diagnosis and Treatment Gaps
3
CagriSema Cuts Weight Up to 27% Across Menopause Stages: TMS 2026
4
Elinzanetant for Menopause-Related VMS: Onset of Relief and Adverse Effects
5